


PRODUCT INFORMATION



BQ-3020 (trifluoroacetate salt)

Item No. 34014

Formal Name: N-acetyl-11-L-alanine-15-L-alanine-6-21-endothelin 1 (swine reduced), trifluoroacetate salt
MF: $C_{96}H_{140}N_{20}O_{25}S \cdot XCF_3COOH$
FW: 2,006.3
Purity: $\geq 90\%$
Supplied as: A solid
Storage: $-20^{\circ}C$
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BQ-3020 (trifluoroacetate salt) is supplied as a solid. A stock solution may be made by dissolving the BQ-3020 (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. BQ-3020 (trifluoroacetate salt) is soluble in the organic solvent DMSO. The solubility of BQ-3020 (trifluoroacetate salt) in DMSO is approximately 25 mg/ml.

BQ-3020 (trifluoroacetate salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BQ-3020 (trifluoroacetate salt) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. BQ-3020 (trifluoroacetate salt) has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BQ-3020 is a peptide endothelin type B (ET_B) receptor agonist.¹ It selectively binds to ET_B over ET_A receptors ($IC_{50}s = 0.07$ and 940 nM, respectively) and induces inositol triphosphate formation and calcium mobilization in isolated bovine carotid artery endothelial cells.^{1,2} BQ-3020 increases or decreases renal perfusion pressure in Dahl salt-resistant or -sensitive rats, respectively.³ It decreases the production of nitric oxide (NO) and induces vasoconstriction in a rat model of diet-induced hypercholesterolemia.

References

1. Ihara, M., Saek, T., Fukuroda, T., *et al.* A novel radioligand [^{125}I]BQ-3020 selective for endothelin (ET_B) receptors. *Life Sci.* **51(6)**, PL47-PL52 (1992).
2. Hirata, Y., Emori, T., Eguchi, S., *et al.* Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. *J. Clin. Invest.* **91(4)**, 1367-1373 (1993).
3. Kakoki, M., Hirata, Y., Hayakawa, H., *et al.* Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. *Circulation* **99(9)**, 1242-1248 (1999).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/08/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM